全文获取类型
收费全文 | 394771篇 |
免费 | 23480篇 |
国内免费 | 13239篇 |
专业分类
耳鼻咽喉 | 2876篇 |
儿科学 | 10028篇 |
妇产科学 | 5408篇 |
基础医学 | 44031篇 |
口腔科学 | 5302篇 |
临床医学 | 40858篇 |
内科学 | 58750篇 |
皮肤病学 | 3039篇 |
神经病学 | 25834篇 |
特种医学 | 16253篇 |
外国民族医学 | 79篇 |
外科学 | 47318篇 |
综合类 | 44018篇 |
现状与发展 | 50篇 |
一般理论 | 16篇 |
预防医学 | 36398篇 |
眼科学 | 8055篇 |
药学 | 35515篇 |
272篇 | |
中国医学 | 15463篇 |
肿瘤学 | 31927篇 |
出版年
2024年 | 914篇 |
2023年 | 3430篇 |
2022年 | 8777篇 |
2021年 | 11064篇 |
2020年 | 8503篇 |
2019年 | 7023篇 |
2018年 | 28713篇 |
2017年 | 24211篇 |
2016年 | 25758篇 |
2015年 | 10796篇 |
2014年 | 13121篇 |
2013年 | 13417篇 |
2012年 | 24641篇 |
2011年 | 39461篇 |
2010年 | 32275篇 |
2009年 | 22796篇 |
2008年 | 32504篇 |
2007年 | 34498篇 |
2006年 | 12305篇 |
2005年 | 12358篇 |
2004年 | 10978篇 |
2003年 | 11463篇 |
2002年 | 8442篇 |
2001年 | 5146篇 |
2000年 | 4504篇 |
1999年 | 3558篇 |
1998年 | 2238篇 |
1997年 | 2359篇 |
1996年 | 1660篇 |
1995年 | 1549篇 |
1994年 | 1440篇 |
1993年 | 965篇 |
1992年 | 1102篇 |
1991年 | 1062篇 |
1990年 | 1005篇 |
1989年 | 875篇 |
1988年 | 768篇 |
1987年 | 649篇 |
1986年 | 586篇 |
1985年 | 484篇 |
1984年 | 404篇 |
1983年 | 327篇 |
1982年 | 301篇 |
1981年 | 241篇 |
1980年 | 240篇 |
1979年 | 203篇 |
1978年 | 202篇 |
1977年 | 220篇 |
1976年 | 199篇 |
1974年 | 180篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
51.
冯莹 《中国实用外科杂志》2020,40(5):531-536
易栓症是外科围手术期静脉血栓栓塞症(VTE)的防治重点。对于接受手术的止凝血障碍病人,需要谨慎评估VTE的个体风险,同时兼顾手术和麻醉的性质、出血障碍类型和严重程度、年龄、体重指数(BMI)、血栓形成史、恶性肿瘤和其他高危共患病。VTE风险应与已知出血障碍病人使用抗凝相关的出血风险平衡。实验室检查有助于发现和判断血栓与出血的病因,对病人的止凝血代偿能力作出评估,并对抗凝药物的合理使用提供依据。对上述病人,建议术后不常规使用药物预防血栓,尤其是血友病病人,但围手术期因子替代和止血药物的过度应用仍存在导致血栓的风险。使用低分子肝素(LMWH)和直接口服抗凝剂前应评估肾小球滤过率。当血小板计数<50×109/L,LMWH短期减量应用可能相对安全,监测抗Хa水平可用于调整中重度血小板减少症病人LMWH的剂量。主要消化道出血停止和重新使用华法林应至少相隔7 d。对于高血栓栓塞风险和术后高出血风险病人,术后当晚和术后第1天减量应用直接口服抗凝剂是一种可取的做法。 相似文献
52.
53.
Richard Kim Elaine Tan Emily Wang Amit Mahipal Dung-Tsa Chen Biwei Cao Fadzai Masawi Cindy Machado James Yu Dae Won Kim 《The oncologist》2020,25(12):e1893-e1899
Lessons Learned
- The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
- Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
- The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
54.
目的分析成人血液系统恶性肿瘤患者接受强烈化疗后中性粒细胞减少性肠炎(NE)的发生率、危险因素及预后情况。方法收集2004至2013年接受化疗的1804例血液系统恶性肿瘤患者,记录患者血常规、凝血检测和血液生化检测结果,并记录患者年龄、性别、原发病、既往化疗次数、既往化疗方案中是否使用阿糖胞苷、临床症状、肠壁厚度、中性粒细胞最低计数、中性粒细胞缺乏持续时间、NE的治疗方法和预后等,探讨NE起病诱因、临床特征、腹部B超特点、症状的预后意义及化疗药物对发病的影响等。结果1804例患者中226例(12.5%)化疗后合并NE,化疗后10~19d起病,中位起病时间为化疗后第14天。发生NE后26例患者死亡,病死率11.5%。化疗药物包括阿糖胞苷、临床症状≥4项、中性粒细胞缺乏持续超过7d以及B超下肠壁厚度≥10mm的患者病死率相对较高。结论NE是接受强烈化疗的血液系统肿瘤患者的严重的并发症,发生NE后患者病死率较高。 相似文献
55.
N. S. Hari Narayana Moorthy Sergio F. Sousa Maria J. Ramos Pedro A. Fernandes 《Medicinal chemistry research》2016,25(7):1340-1357
Farnesyltransferase (FTase) is one of the prenyltransferase family enzymes that catalyse the transfer of 15-membered isoprenoid (farnesyl) moiety to the cysteine of CAAX motif-containing proteins including Rho and Ras family of G proteins. Inhibitors of FTase act as drugs for cancer, malaria, progeria and other diseases. In the present investigation, we have developed two structure-based pharmacophore models from protein–ligand complex (3E33 and 3E37) obtained from the protein data bank. Molecular dynamics (MD) simulations were performed on the complexes, and different conformers of the same complex were generated. These conformers were undergone protein–ligand interaction fingerprint (PLIF) analysis, and the fingerprint bits have been used for structure-based pharmacophore model development. The PLIF results showed that Lys164, Tyr166, TrpB106 and TyrB361 are the major interacting residues in both the complexes. The RMSD and RMSF analyses on the MD-simulated systems showed that the absence of FPP in the complex 3E37 has significant effect in the conformational changes of the ligands. During this conformational change, some interactions between the protein and the ligands are lost, but regained after some simulations (after 2 ns). The structure-based pharmacophore models showed that the hydrophobic and acceptor contours are predominantly present in the models. The pharmacophore models were validated using reference compounds, which significantly identified as HITs with smaller RMSD values. The developed structure-based pharmacophore models are significant, and the methodology used in this study is novel from the existing methods (the original X-ray crystallographic coordination of the ligands is used for the model building). In our study, along with the original coordination of the ligand, different conformers of the same complex (protein–ligand) are used. It concluded that the developed methodology is significant for the virtual screening of novel molecules on different targets. 相似文献
56.
57.
58.
59.
Valerie Iles 《Health care analysis》2016,24(2):105-118
This paper takes a somewhat slant perspective on flourishing and care in the context of suffering, death and dying, arguing that care in this context consists principally of ‘acts of work and courage that enable flourishing’. Starting with the perception that individuals, society and health care professionals have become dulled to death and the process of dying in Western advanced health systems, it suggests that for flourishing to occur, both of these aspects of life need to be faced more directly. The last days of life need to be ‘undulled’. Reflections upon the experiences of the author as carer and daughter in the face of her mother’s experience of death are used as basis for making suggestions about how care systems and professionals might better assist people in dealing with ‘the most grown up thing’ humans ever do, which is to die. 相似文献
60.